Literature DB >> 17387369

Clinical experience with gene therapy for the treatment of prostate cancer.

Matthew A Stanizzi1, Simon J Hall.   

Abstract

Localized prostate cancer can be treated effectively with radical prostatectomy or radiation therapy. The treatment options for metastatic prostate cancer are limited to hormonal therapy; hormone-refractory cancer is treated with taxane-based chemotherapy, which provides only a modest survival benefit. New treatments are needed. The gene for the initiation of prostate cancer has not been identified; however, gene therapy can involve tumor injection of a gene to kill cells, systemic gene delivery to target and kill metastases, or local gene expression intended to generate a systemic response. This review will provide an overview of the various strategies of cancer gene therapy, focusing on those that have gone to clinical trial, detailing clinical experience in prostate cancer patients.

Entities:  

Year:  2007        PMID: 17387369      PMCID: PMC1831538     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  43 in total

1.  Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Authors:  M G Sanda; D C Smith; L G Charles; C Hwang; K J Pienta; J Schlom; D Milenic; D Panicali; J E Montie
Journal:  Urology       Date:  1999-02       Impact factor: 2.649

2.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

3.  Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

4.  In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

Authors:  J R Herman; H L Adler; E Aguilar-Cordova; A Rojas-Martinez; S Woo; T L Timme; T M Wheeler; T C Thompson; P T Scardino
Journal:  Hum Gene Ther       Date:  1999-05-01       Impact factor: 5.695

5.  Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.

Authors:  Jonathan W Simons; Michael A Carducci; Bahar Mikhak; Michael Lim; Barbara Biedrzycki; Flavia Borellini; Shirley M Clift; Kristen M Hege; Dale G Ando; Steven Piantadosi; Richard Mulligan; William G Nelson
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

6.  A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

Authors:  T L DeWeese; H van der Poel; S Li; B Mikhak; R Drew; M Goemann; U Hamper; R DeJong; N Detorie; R Rodriguez; T Haulk; A M DeMarzo; S Piantadosi; D C Yu; Y Chen; D R Henderson; M A Carducci; W G Nelson; J W Simons
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Authors:  Bin S Teh; Gustavo Ayala; Laura Aguilar; Wei-Yuan Mai; Terry L Timme; Maria T Vlachaki; Brian Miles; Dov Kadmon; Thomas Wheeler; James Caillouet; Maria Davis; L Steven Carpenter; Hsin H Lu; J Kam Chiu; Shiao Y Woo; Timothy Thompson; Estuardo Aguilar-Cordova; E Brian Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-04-01       Impact factor: 7.038

9.  Reovirus therapy of tumors with activated Ras pathway.

Authors:  M C Coffey; J E Strong; P A Forsyth; P W Lee
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

10.  Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

Authors:  Howard L Kaufman; Wei Wang; Judith Manola; Robert S DiPaola; Yoo-Joung Ko; Christopher Sweeney; Theresa L Whiteside; Jeffrey Schlom; George Wilding; Louis M Weiner
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

View more
  1 in total

1.  Functional characterization of the GDEP promoter and three enhancer elements in retinoblastoma and prostate cell lines.

Authors:  D S Cross; J K Burmester
Journal:  Med Oncol       Date:  2007-06-27       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.